ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD37/DXd Antibody-drug Conjugate DS3790

Its studies are mostly in Hematologic Neoplasms, led by Daiichi Sankyo.

Furthest: phase 2, since Oct 21, 20251 company-led study, 1 open or runningNext primary completion: Nov 30, 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Daiichi Sankyo11 open or runningphase 2since Oct 21, 2025Oct 21, 2025Nov 30, 2030phase 2 · NCT07220616

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 21, 2025First study: phase 2 study in Hematologic NeoplasmsFirst studyNCT07220616 · 420 planned · United States, France, Italy and more

Ahead

  1. Nov 30, 2030Primary completion: phase 2 study in Hematologic NeoplasmsNCT07220616

TargetBeta

CD37 →read by rule
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) CD37 ”NCIt, by rule

Other programs on CD37

ProgramCompanyFurthest phaseStudies
Anti-CD37/DM1 Derivative Antibody-drug Conjugate Debio 1562MruleDebiopharmphase 21

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07220616Hematologic Neoplasms · United States, France, Italy and more2RecruitingNov 30, 2030420

How it is read

Names in the registry

  • “DS3790a”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.